Statistiche di base
| LEI | 549300GRM36VBKISYJ58 |
| CIK | 1356576 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Supernus Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| May 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2026 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or organ |
|
| May 5, 2026 |
Supernus Announces First Quarter 2026 Financial Results Exhibit 99.1 Supernus Announces First Quarter 2026 Financial Results •Total revenues were $207.7 million in the first quarter 2026, a 39% increase compared to same period last year. •Combined revenues of the Company's four growth products increased to $149.1 million in the first quarter 2026, representing an increase of 56% compared to the same period last year. This strong growth was driven by an |
|
| May 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2026 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or organi |
|
| May 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35518 SUPERNUS PHARMACEUTICALS, INC. |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 FILED BY THE REGISTRANT ☒ FILED BY A PARTY OTHER THAN THE REGISTRANT ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| April 30, 2026 |
2025 ANNUAL REPORT ANNIVERSARY TH THDearSupernusStockholder, Wehadanoutstanding2025withsignificantprogressmadeagainstourstrategicobjectives. |
|
| April 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2026 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or org |
|
| April 22, 2026 |
Exhibit 99.1 Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026 ROCKVILLE, Md., April 22, 2026 – Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report first quarter 2026 |
|
| April 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2026 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or orga |
|
| April 7, 2026 |
Exhibit 2.1 CERTAIN CONFIDENTIAL INFORMATION IDENTIFIED IN THIS DOCUMENT MARKED BY ***, HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (this “Agreement”), dated effective as of April 1, 2026, is entered into by and between Navitor Pharmaceuticals, Inc., a Del |
|
| March 2, 2026 |
EXHIBIT 21 SIGNIFICANT SUBSIDIARIES OF SUPERNUS PHARMACEUTICALS, INC. Name of Subsidiaries Jurisdiction of Organization Sage Therapeutics, LLC Delaware Sage Securities Corporation Massachusetts MDD US Enterprises, LLC Delaware MDD US Operations, LLC Delaware Adamas Pharmaceuticals, LLC Delaware Adamas Operations, LLC Delaware Adamas Holdings, LLC Delaware Biscayne Neurotherapeutics, Inc. Delaware |
|
| March 2, 2026 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2025 or ☐ TRANSMISSION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-35518 SUPER |
|
| February 24, 2026 |
Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results Exhibit 99.1 Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results •Record total revenues of $211.6 million and $719.0 million in the fourth quarter and full year 2025, a 21% and 9% increase compared to same periods last year. •Combined revenues of the Company's four growth products increased to $161.3 million and $521.8 million in the fourth quarter and full year 2025, rep |
|
| February 24, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2026 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or |
|
| February 24, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2026 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or |
|
| February 12, 2026 |
Exhibit 99.1 Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026 ROCKVILLE, Md., February 12, 2026 – Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Compa |
|
| February 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2026 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or |
|
| January 28, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2026 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or o |
|
| January 28, 2026 |
firstamendmenttoagreemen CERTAIN CONFIDENTIAL INFORMATION IDENTIFIED IN THIS DOCUMENT MARKED BY *** , HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| November 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35518 SUPERNUS PHARMACEUTICALS, INC. |
|
| November 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2025 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or o |
|
| November 4, 2025 |
Supernus Announces Third Quarter 2025 Financial Results Exhibit 99.1 Supernus Announces Third Quarter 2025 Financial Results •Combined revenues of the Company's four growth products increased 52% to $149.2 million in the third quarter of 2025, compared to the same period in 2024. This strong growth was driven by an increase in net sales of Qelbree® and GOCOVRI®, and the addition of sales from ZURZUVAE® and ONAPGO™. •Total revenues were $192.1 million i |
|
| October 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2025 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or o |
|
| October 21, 2025 |
Exhibit 99.1 Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 ROCKVILLE, Md., October 21, 2025 – Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to rep |
|
| October 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or or |
|
| October 16, 2025 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.4 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Introduction On July 31, 2025, Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") completed the acquisition ("Acquisition") of Sage Therapeutics, Inc. ("Sage"). The following unaudited pro forma condensed combined statements of operations (pro forma statements of operations) and condensed combined balance sheet (pr |
|
| October 9, 2025 |
144 0001005544 XXXXXXXX LIVE 0001356576 SUPERNUS PHARMACEUTICALS, INC. 001-35518 9715 Key West Avenue Rockville MD 20850 3018382500 CHARLES NEWHALL Director Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 25000 1200000.00 56073088 10/09/2025 NASDAQ Common 05/01/2012 In-Kind Distribution NEA Partners N 25000 05/01/2012 N/A N 10b5-1 Sa |
|
| October 9, 2025 |
144 0001539937 XXXXXXXX LIVE 0001356576 SUPERNUS PHARMACEUTICALS, INC. 001-35518 9715 Key West Avenue Rockville MD 20850 3018382500 JACK A. KHATTAR Director Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 59900 2875200.00 56073088 10/09/2025 NASDAQ Common 10/09/2025 Exercise of Stock Options Issuer N 59900 10/09/2025 Cash N 1 |
|
| October 2, 2025 |
144 0001539937 XXXXXXXX LIVE 0001356576 SUPERNUS PHARMACEUTICALS, INC. 001-35518 9715 Key West Avenue Rockville MD 20850 3018382500 JACK A. KHATTAR Director Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 1904 91468.16 56073088 10/02/2025 NASDAQ Common 10/02/2025 Exercise of Stock Options Issuer N 1904 10/02/2025 Cash N 10b5- |
|
| October 1, 2025 |
144 0001539937 XXXXXXXX LIVE 0001356576 SUPERNUS PHARMACEUTICALS, INC. 001-35518 9715 Key West Avenue Rockville MD 20850 3018382500 JACK A. KHATTAR Director Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 40173 1919867.67 56073088 10/01/2025 NASDAQ Common 10/01/2025 Exercise of Stock Options Issuer N 40173 10/01/2025 Cash N 1 |
|
| September 30, 2025 |
144 0001539937 XXXXXXXX LIVE 0001356576 SUPERNUS PHARMACEUTICALS, INC. 001-35518 9715 Key West Avenue Rockville MD 20850 3018382500 JACK A. KHATTAR Director Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 8588 408788.80 56073088 09/30/2025 NASDAQ Common 09/30/2025 Exercise of Stock Options Issuer N 8588 09/30/2025 Cash N 10b5 |
|
| September 29, 2025 |
144 0001539937 XXXXXXXX LIVE 0001356576 SUPERNUS PHARMACEUTICALS, INC. 001-35518 9715 Key West Avenue Rockville MD 20850 3018382500 JACK A. KHATTAR Director Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 10235 481352.05 56073088 09/29/2025 NASDAQ Common 09/29/2025 Exercise of Stock Options Issuer N 10235 09/29/2025 Cash N 10 |
|
| September 23, 2025 |
144 0001539937 XXXXXXXX LIVE 0001356576 SUPERNUS PHARMACEUTICALS, INC. 001-35518 9715 Key West Avenue Rockville MD 20850 3018382500 JACK A. KHATTAR Director Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 29513 1386520.74 56073088 09/23/2025 NASDAQ Common 09/23/2025 Exercise of Stock Options Issuer N 29513 09/23/2025 Cash N 1 |
|
| September 22, 2025 |
144 0001539937 XXXXXXXX LIVE 0001356576 SUPERNUS PHARMACEUTICALS, INC. 001-35518 9715 Key West Avenue Rockville MD 20850 3018382500 JACK A KHATTAR Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 16587 763665.48 56073088 09/22/2025 NASDAQ Common 09/22/2025 Exercise of Stock Options Issuer N 16587 09/22/2025 Cash N 10b5-1 Sales |
|
| September 12, 2025 |
144 0001804567 XXXXXXXX LIVE 0001356576 SUPERNUS PHARMACEUTICALS, INC. 001-35518 9715 Key West Avenue Rockville MD 20850 301-838-2500 FRANK MOTTOLA Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 5000 229338.50 56073088 09/12/2025 NASDAQ Common 09/12/2025 Exercise of options under a registered plan Issuer N 5000 09/12/2025 Ca |
|
| September 8, 2025 |
144 0001539937 XXXXXXXX LIVE 0001356576 Supernus Pharmaceuticals, Inc. 001-35518 9715 Key West Avenue Rockville MD 20850 3018382500 JACK A KHATTAR Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 6322 290812.00 56073088 09/08/2025 NASDAQ Common 09/08/2025 Exercise of Stock Options Issuer N 6322 09/08/2025 Cash N 10b5-1 Sales f |
|
| September 5, 2025 |
144 0001539937 XXXXXXXX LIVE 0001356576 SUPERNUS PHARMACEUTICALS, INC. 001-35518 9715 Key West Avenue Rockville MD 20850 3018382500 JACK A KHATTAR Director Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 55578 2524908.54 56073088 09/05/2025 NASDAQ Common 09/05/2025 Exercise of Stock Options Issuer N 55578 09/05/2025 Cash N 10 |
|
| August 28, 2025 |
144 0001539937 XXXXXXXX LIVE 0001356576 SUPERNUS PHARMACEUTICALS, INC. 001-35518 9715 Key West Avenue Rockville MD 20850 3018382500 JACK A KHATTAR Director Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 24150 1088440.50 56073088 08/28/2025 NASDAQ Common 08/28/2025 Exercise of Stock Options Issuer N 24150 08/28/2025 Cash N 10 |
|
| August 27, 2025 |
144 0001539937 XXXXXXXX LIVE 0001356576 SUPERNUS PHARMACEUTICALS, INC. 001-35518 9715 Key West Avenue Rockville MD 20850 3018382500 JACK A KHATTAR Director Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 10650 472008.00 56073088 08/27/2025 NASDAQ Common 08/27/2025 Exercise of Stock Options Issuer N 10650 08/27/2025 Cash N 10b |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or org |
|
| August 5, 2025 |
Form of Amended and Restated Executive Retention Agreement, dated June 6, 2025 formofamendedandrestated 55081614.3 AMENDED AND RESTATED EXECUTIVE RETENTION AGREEMENT THIS AMENDED AND RESTATED EXECUTIVE RETENTION AGREEMENT (this “Agreement”) is made and entered into this 6 day of June, 2025 (the “Effective Date”) by and between Supernus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [•] (the “Executive”). 1. Definitions. Capitalized terms used in this Agre |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35518 SUPERNUS PHARMACEUTICALS, INC. |
|
| August 5, 2025 |
Supernus Announces Second Quarter 2025 Financial Results Exhibit 99.1 Supernus Announces Second Quarter 2025 Financial Results •Net sales of Qelbree® increased 31% in the second quarter of 2025, compared to the same period in 2024. ◦Net sales of Qelbree of $77.6 million and $142.3 million in the second quarter and first six months of 2025, respectively. •Net sales of GOCOVRI® increased 16% in the second quarter of 2025, compared to the same period in 20 |
|
| August 5, 2025 |
fifthamendmenttotheamend 53116404.6 FIFTH AMENDMENT TO THE AMENDED AND RESTATED EMPLOYMENT AGREEMENT This FIFTH AMENDMENT TO THE AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Fifth Amendment”) is made as of July 10, 2025 (the “Effective Date”) by and between Supernus Pharmaceuticals, Inc. a Delaware corporation (the “Company”), and Jack Khattar (the “Executive”). In consideration of the mutual c |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2025 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or orga |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or orga |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) SAGE THERAPEUTICS, INC. (Name of Subject Company (Issuer)) SAPHIRE, INC. (Offeror) A Wholly Owned Subsidiary of SUPERNUS PHARMACEUTICALS, INC. (Parent of Offeror) (Names of Filing Persons) Common Stock |
|
| July 31, 2025 |
Exhibit 10.1 CVR AGREEMENT THIS CVR AGREEMENT (“Agreement”) is made and entered into as of July 30, 2025, by and between: Supernus Pharmaceuticals, Inc., a Delaware corporation (“Parent”) and Equiniti Trust Company, LLC, a New York limited liability trust company, as Rights Agent (as defined herein). Capitalized terms used but not defined herein shall have the meanings assigned to such terms in th |
|
| July 31, 2025 |
Exhibit 99.1 Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics Acquisition strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform, accelerating mid- to long-term revenue and cash flow growth and further diversifying revenue base ROCKVILLE, Md., July 31, 2025 – Supernus |
|
| July 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(l) or 13(e)(l) of the Securities Exchange Act of 1934 (Amendment No. 1) SAGE THERAPEUTICS, INC. (Name of Subject Company (Issuer)) SAPHIRE INC. (Offeror) A Wholly Owned Subsidiary of SUPERNUS PHARMACEUTICALS, INC. (Parent of Offeror) (Names of Filing Persons) Common Stock |
|
| July 28, 2025 |
Press Release issued by Supernus Pharmaceuticals, Inc. on July 28, 2025. Exhibit 99.(a)(5)(C) Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer ROCKVILLE, Md., July 28, 2025 - Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ: SUPN) ("Supernus", and the "Company"), today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amend |
|
| July 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2025 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or orga |
|
| July 22, 2025 |
Exhibit 99.1 Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025 ROCKVILLE, Md., July 22, 2025 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expect |
|
| July 2, 2025 |
Form of Contingent Value Rights Agreement.* Exhibit 99.(d)(2) CONFIDENTIAL ANNEX III FORM OF CVR AGREEMENT THIS CVR AGREEMENT (“Agreement”) is made and entered into as of [●], 2025, by and between: Supernus Pharmaceuticals, Inc., a Delaware corporation (“Parent”) and [Rights Agent], a [●], as Rights Agent (as defined herein). Capitalized terms used but not defined herein shall have the meanings assigned to such terms in the Merger Agreement |
|
| July 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SAGE THERAPEUTICS, INC. (Name of Subject Company (Issuer)) Saphire, Inc. (Offeror) A Wholly Owned Subsidiary of SUPERNUS PHARMACEUTICALS, INC. (Parent of Offeror) Common Stock par value $0.0001 per share (Title of Class |
|
| July 2, 2025 |
Calculation of Filing Fee Tables Table 1: Transaction Valuation Transaction Valuation Fee Rate Amount of Filing Fee Fees to be Paid 1 $ 607,928,005. |
|
| July 2, 2025 |
Offer to Purchase, dated July 2, 2025.* TABLE OF CONTENTS Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of SAGE THERAPEUTICS, INC. |
|
| July 2, 2025 |
Exhibit 99.(d)(4) CONFIDENTIAL February 5, 2025 Supernus Pharmaceuticals, Inc. 9715 Key West Avenue Rockville, MD 20850 Re: Confidentiality Agreement Supernus Pharmaceuticals, Inc. (referred to herein as “you or your”) has requested certain Evaluation Material (as defined below) from Sage Therapeutics, Inc. (together with its subsidiaries, the “Company”) in connection with the evaluation, negotiat |
|
| July 2, 2025 |
Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of SAGE THERAPEUTICS, INC. |
|
| July 2, 2025 |
Exhibit 99.(d)(3) 4985741v1 MUTUAL NON-DISCLOSURE AGREEMENT This MUTUAL NON-DISCLOSURE AGREEMENT is made and entered into as of January 24, 2025 (the “Effective Date”), between Sage Therapeutics, Inc. (“SAGE”), with offices at 55 Cambridge Parkway, Cambridge, MA, and Supernus Pharmaceuticals, Inc. (“Supernus”), with offices at 9715 Key West Avenue, Rockville, MD 20850. SAGE and Supernus may be ref |
|
| July 2, 2025 |
Summary Advertisement, published in the Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| July 2, 2025 |
Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.* Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of SAGE THERAPEUTICS, INC. |
|
| July 2, 2025 |
Exhibit (a)(1)(B) Letter of Transmittal to Tender Shares of Common Stock of SAGE THERAPEUTICS, INC. |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2025 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or orga |
|
| June 16, 2025 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER among: Sage Therapeutics, Inc., a Delaware corporation; Supernus Pharmaceuticals, Inc., a Delaware corporation; and Saphire, Inc., a Delaware corporation Dated as of June 13, 2025 Table of Contents Section 1 THE OFFER 1.1 The Offer 2 1.2 Company Actions 5 Section 2 MERGER TRANSACTION 2.1 Merger of Purchaser into the Company 6 2.2 Effect of |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SAGE THERAPEUTICS, INC. (Name of Subject Company (Issuer)) Saphire, Inc. (Offeror) a wholly-owned subsidiary of SUPERNUS PHARMACEUTICALS, INC. (Parent of Offeror) (Names of Filing Persons) Common Stock par value $0.0001 |
|
| June 16, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or orga |
|
| June 16, 2025 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER among: Sage Therapeutics, Inc., a Delaware corporation; Supernus Pharmaceuticals, Inc., a Delaware corporation; and Saphire, Inc., a Delaware corporation Dated as of June 13, 2025 Table of Contents Section 1 THE OFFER 1.1 The Offer 2 1.2 Company Actions 5 Section 2 MERGER TRANSACTION 2.1 Merger of Purchaser into the Company 6 2.2 Effect of |
|
| June 16, 2025 |
Exhibit 99.1 Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio § Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base. § Strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS |
|
| June 16, 2025 |
Exhibit 99.2 © 2025 Supernus Pharmaceuticals, Inc. All Rights Reserved. Acquisition of Sage Therapeutics, Inc. June 16, 2025 ©2025 Supernus Pharmaceuticals, Inc. All Rights Reserved. 2 This presentation and other matters discussed today or answers that may be given to questions asked include forward - looking statements within the meaning of the federal securities laws. These statements, among oth |
|
| June 16, 2025 |
Note to Sage Employees sent on June 16, 2025. Exhibit 99.(a)(5)(d) June 16, 2025 Dear Colleagues, Today’s announcement marks a historic milestone in the treatment of postpartum depression (PPD). Supernus and Sage agreed to unite to continue the fight against a condition that ails millions of women worldwide. You have our commitment that we will continue the incredible work that you started by creating Zurzuvae® and making it available to wome |
|
| June 16, 2025 |
Exhibit 99.2 © 2025 Supernus Pharmaceuticals, Inc. All Rights Reserved. Acquisition of Sage Therapeutics, Inc. June 16, 2025 ©2025 Supernus Pharmaceuticals, Inc. All Rights Reserved. 2 This presentation and other matters discussed today or answers that may be given to questions asked include forward - looking statements within the meaning of the federal securities laws. These statements, among oth |
|
| June 16, 2025 |
Transcript of Supernus Inc. Investor Presentation on June 16, 2025. Exhibit 99.(a)(5)(c) Transcript of Supernus Inc. Investor Presentation on June 16, 2025. Operator: Good morning, everyone and welcome to Supernus Business Update Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Instructions will follow at that time. As a reminder, this conference call is being recorded. I would now lik |
|
| June 16, 2025 |
Exhibit 99.1 Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio § Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base. § Strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or orga |
|
| May 28, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or organ |
|
| May 28, 2025 |
Supernus Announces Paragraph IV ANDA Filings for Qelbree® Exhibit 99.1 Supernus Announces Paragraph IV ANDA Filings for Qelbree® ROCKVILLE, MD, May 28, 2025 – Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company received Paragraph IV Notice Letters from third parties notifying Supernus that |
|
| May 6, 2025 |
Supernus Announces First Quarter 2025 Financial Results Exhibit 99.1 Supernus Announces First Quarter 2025 Financial Results •First quarter 2025 net sales of Qelbree® increased 44% to $64.7 million, compared to the same period in 2024. •First quarter 2025 net sales of GOCOVRI® increased 16% to $30.7 million, compared to the same period in 2024. •First quarter 2025 total revenues increased 4% to $149.8 million, compared to the same period in 2024. First |
|
| May 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or organi |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35518 SUPERNUS PHARMACEUTICALS, INC. |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 FILED BY THE REGISTRANT ☒ FILED BY A PARTY OTHER THAN THE REGISTRANT ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 30, 2025 |
2024 ANNUAL REPORTDearSupernus Stockholder, Wearepleasedwithour2024resultswhichreflectsolidcommercialexecutionacrossthecompany,including continued growth of our core products and strong growth in operating earnings. |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 FILED BY THE REGISTRANT x FILED BY A PARTY OTHER THAN THE REGISTRANT ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| April 23, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2025 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or org |
|
| April 23, 2025 |
Exhibit 99.1 Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025 ROCKVILLE, Md., April 23, 2025 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects t |
|
| February 25, 2025 |
Subsidiaries of the Registrant. EXHIBIT 21 SIGNIFICANT SUBSIDIARIES OF SUPERNUS PHARMACEUTICALS, INC. Name of Subsidiaries Jurisdiction of Organization MDD US Enterprises, LLC Delaware MDD US Operations, LLC Delaware Supernus Europe Ltd. United Kingdom Adamas Pharmaceuticals, LLC Delaware Adamas Operations, LLC Delaware Adamas Holdings, LLC Delaware Biscayne Neurotherapeutics, Inc. Delaware |
|
| February 25, 2025 |
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results Exhibit 99.1 Supernus Announces Fourth Quarter and Full Year 2024 Financial Results •Fourth quarter 2024 net sales of Qelbree® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of Qelbree increased 72% to $241.3 million, compared to full year 2023. •Fourth quarter 2024 net sales of GOCOVRI® increased 15% to $36.9 million, compared to the same period in 2 |
|
| February 25, 2025 |
Incentive Compensation Recoupment Policy. Incentive Compensation Recoupment Policy of Supernus Pharmaceuticals, Inc. Recitals Whereas, the Board of Directors (the “Board”) of Supernus Pharmaceuticals, Inc. (the “Company”) believes that it is in the best interests of the Company and its stockholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensati |
|
| February 25, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or |
|
| February 25, 2025 |
EXHIBIT 19 SUPERNUS PHARMACEUTICALS, INC. Policy Statement on Securities Trades by Directors, Officers and Employees THE LAW AND COMPANY POLICY ON SECURITIES TRADING It is against the law and the policy of Supernus Pharmaceuticals, Inc. (the “Company”) for any employee, officer, or director of the Company or any consultant to the Company to buy or sell common stock or other securities of the Compa |
|
| February 25, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2024 or ☐ TRANSMISSION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-35518 SUPER |
|
| February 24, 2025 |
As filed with the Securities and Exchange Commission on February 24, 2025 As filed with the Securities and Exchange Commission on February 24, 2025 Registration No. |
|
| February 24, 2025 |
SUPERNUS PHARMACEUTICALS, INC. 2021 EQUITY INCENTIVE PLAN PERFORMANCE SHARE UNIT AWARD AGREEMENT This Performance Share Unit Award Agreement (the “Agreement”) is made and entered into as of , (the “Grant Date”). This Agreement evidences a performance share unit Award granted by Supernus Pharmaceuticals, Inc. (the “Company”) to the undersigned (“Participant”) pursuant to and subject to the terms of |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or |
|
| February 18, 2025 |
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression Exhibit 99.1 Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression •Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placebo •SPN-820 was well-tolerated with few adverse events, consistent with previously reported studies ROCKVILLE, Md., |
|
| February 18, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or |
|
| February 11, 2025 |
Exhibit 99.1 Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results ROCKVILLE, Md., February 11, 2025 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced tha |
|
| February 11, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2025 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or |
|
| February 4, 2025 |
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease Exhibit 99.1 Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease •ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s disease •ONAPGO is a wearable subcutaneous infusion device that provides continuous treatment during the waking day for more consistent control o |
|
| February 4, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2025 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or o |
|
| January 27, 2025 |
Exhibit 99.1 Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women January 27, 2025 •Updated label includes new data in Section 12.2, detailing serotonin 5-HT2C partial agonist activity and norepinephrine transporter inhibition, highlighting Qelbree’s multimodal pharmacodynamics •Qelbree is the first A |
|
| January 27, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2025 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or o |
|
| December 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2024 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or |
|
| December 20, 2024 |
Code of Ethics and Business Conduct Code of Ethics & Business Conduct Any violations of this Code must be reported to your immediate supervisor, if any, or the Compliance Hotline, 1-866-822-4512 CODE OF ETHICS & BUSINESS CONDUCT 1 Corporate Compliance Policies & Guidelines 52514257. |
|
| November 14, 2024 |
SUPN / Supernus Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-supn093024a5.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* SUPERNUS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 868459108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Stateme |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35518 SUPERNUS PHARMACEUTICALS, INC. |
|
| November 4, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or o |
|
| November 4, 2024 |
Supernus Announces Third Quarter 2024 Financial Results Exhibit 99.1 Supernus Announces Third Quarter 2024 Financial Results •Net sales of Qelbree® increased 68% in the third quarter of 2024, compared to the same period in 2023. ◦Net sales of Qelbree of $62.4 million and $166.9 million in the third quarter and first nine months of 2024, respectively. •Net sales of GOCOVRI® increased 8% in the third quarter of 2024, compared to the same period in 2023. |
|
| November 1, 2024 |
EX-99.A 2 d885694dex99a.htm EX-99.A EXHIBIT A AGREEMENT TO FILE JOINT ACQUISITION STATEMENTS AGREEMENT made this [7th] day of FEBRUARY, 2024 by and between Delaware Funds by Macquarie,® Optimum Fund Trust and Macquarie ETF Trust listed on Annex A hereto, Macquarie Investment Management Business Trust, Macquarie Management Holdings, Inc, and the Macquarie Parties listed on Annex B hereto (collectiv |
|
| November 1, 2024 |
SUPN / Supernus Pharmaceuticals, Inc. / MACQUARIE GROUP LTD - SC 13G/A Passive Investment SC 13G/A 1 d885694dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Supernus Pharmaceuticals Inc (Name of Issuer) Common Shares (Title of Class of Securities) 868459108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| November 1, 2024 |
EX-99.B 3 d885694dex99b.htm EX-99.B EXHIBIT B Powers of Attorney for Macquarie Group Limited incorporated by reference to 13G filings made by Macquarie Group Limited on June 7, 2023. Page 13 of 13 |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Supernus Pharmaceuticals Inc (Name of Issuer) Common Stock (Title of Class of Securities) 868459108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or o |
|
| October 21, 2024 |
Exhibit 99.1 Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results ROCKVILLE, Md., October 21, 2024 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expe |
|
| October 21, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2024 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or o |
|
| October 17, 2024 |
Exhibit 99.1 Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms SPN-820 was well-tolerated with few adverse events SPN-820 is a novel, first-in-class intracellular modulator of mTORC1 for the treatment of depression Company to host webcast today at 4:3 |
|
| October 17, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2024 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or o |
|
| October 10, 2024 |
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder ROCKVILLE, Md. |
|
| October 10, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2024 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or o |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2024 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or or |
|
| August 19, 2024 |
Exhibit 99.1 Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA PDUFA Target Action Date of February 1, 2025 ROCKVILLE, Md., August 19, 2024 – Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food a |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or org |
|
| August 6, 2024 |
Supernus Announces Second Quarter 2024 Financial Results Exhibit 99.1 Supernus Announces Second Quarter 2024 Financial Results •Net sales of Qelbree® increased 92% in the second quarter of 2024, compared to the same period in 2023. ◦$59.4 million and $104.5 million of net sales in the second quarter and first six months of 2024, respectively. •Net sales of GOCOVRI® increased 10% in the second quarter of 2024, compared to the same period in 2023. ◦$31.7 |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35518 SUPERNUS PHARMACEUTICALS, INC. |
|
| August 6, 2024 |
EXECUTION COPY CERTAIN CONFIDENTIAL INFORMATION IDENTIFIED IN THIS DOCUMENT MARKED BY [**] , HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| August 1, 2024 |
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device Exhibit 99.1 Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device ROCKVILLE, Md., August 1, 2024 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced it has resubmitted its New Drug Application (NDA) for its apomorphine infusion device (SP |
|
| August 1, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or org |
|
| July 23, 2024 |
Exhibit 99.1 Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024 ROCKVILLE, Md., July 23, 2024 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report |
|
| July 23, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2024 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or orga |
|
| June 17, 2024 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or orga |
|
| June 17, 2024 |
Filing Fee Table (filed herewith) Exhibit 107 Calculation of Filing Fees Table Form S-8 (Form Type) SUPERNUS PHARMACEUTICALS, INC. |
|
| June 17, 2024 |
As filed with the Securities and Exchange Commission on June 17, 2024 As filed with the Securities and Exchange Commission on June 17, 2024 Registration No. |
|
| May 23, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or organ |
|
| May 23, 2024 |
Exhibit 99.1 Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy SPN-817 is a novel, first-in-class highly selective acetylcholinesterase (AChE) inhibitor for epilepsy Company to host webcast today at 4:30 p.m. ET to discuss the interim data ROCKVILLE, Md., May 23, 2024 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company |
|
| May 9, 2024 |
Exhibit 99.1 Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures ROCKVILLE, Md., May 9, 2024 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that th |
|
| May 9, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or organi |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35518 SUPERNUS PHARMACEUTICALS, INC. |
|
| May 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or organi |
|
| May 8, 2024 |
Supernus Announces First Quarter 2024 Financial Results Exhibit 99.1 Supernus Announces First Quarter 2024 Financial Results •Net sales of Qelbree® increased 75% to $45.1 million compared to first quarter 2023. •Total revenues were $143.6 million. Total revenues excluding Trokendi XR® and Oxtellar XR® net product sales (non-GAAP)(1) increased 12% to $100.7 million compared to first quarter 2023. •Operating loss was $(3.2) million. Adjusted operating ea |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 FILED BY THE REGISTRANT ☒ FILED BY A PARTY OTHER THAN THE REGISTRANT ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 FILED BY THE REGISTRANT x FILED BY A PARTY OTHER THAN THE REGISTRANT ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| April 29, 2024 |
DearSupernusStockholder, Weareverypleasedwithourperformancein2023aswecontinuedtosuccessfullytransitionfromour maturebrandsandsetthestagetodelivergrowthin2025andbeyond. |
|
| April 24, 2024 |
Exhibit 99.1 Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 ROCKVILLE, Md., April 24, 2024 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report fin |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2024 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or org |
|
| April 24, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or org |
|
| April 8, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2024 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or orga |
|
| April 8, 2024 |
Supernus Provides Regulatory Update for SPN-830 Exhibit 99.1 Supernus Provides Regulatory Update for SPN-830 ROCKVILLE, Md., April 8, 2024 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced a regulatory update for SPN-830. SPN-830 is an investigational apomorphine infusion device for the contin |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or |
|
| February 27, 2024 |
urities Trades by Directors, Officer EXHIBIT 19 SUPERNUS PHARMACEUTICALS, INC. Policy Statement on Securities Trades by Directors, Officers and Employees THE LAW AND COMPANY POLICY ON SECURITIES TRADING It is against the law and the policy of Supernus Pharmaceuticals, Inc. (the “Company”) for any employee, officer, or director of the Company or any consultant to the Company to buy or sell common stock or other securities of the Compa |
|
| February 27, 2024 |
EXHIBIT 10.38 Type: Time-Based Option Name: Number of Shares of Stock Subject to Option: Price Per Share: Date of Grant: SUPERNUS PHARMACEUTICALS, INC. 2021 EQUITY INCENTIVE PLAN SUPERNUS PHARMACEUTICALS, INC. STRONGLY ENCOURAGES YOU TO SEEK THE ADVICE OF YOUR OWN LEGAL AND FINANCIAL ADVISORS WITH RESPECT TO YOUR AWARD AND ITS TAX CONSEQUENCES. FORM OF TIME-BASED INCENTIVE STOCK OPTION AGREEMENT T |
|
| February 27, 2024 |
EXECUTION COPY EXHIBIT 10.48 CERTAIN CONFIDENTIAL INFORMATION IDENTIFIED IN THIS DOCUMENT MARKED BY [**] , HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SETTLEMENT AGREEMENT BY AND BETWEEN SUPERNUS PHARMACEUTICALS, INC. AND APOTEX INC. APOTEX CORP. DATED AS OF JUNE 21, 2023 EXECUTION COPY THIS SETTLEMENT AGREEM |
|
| February 27, 2024 |
EXHIBIT 10.40 Type: Time-Based Option Name: Number of Shares of Stock Subject to Option: Price Per Share: Date of Grant: SUPERNUS PHARMACEUTICALS, INC. 2021 EQUITY INCENTIVE PLAN SUPERNUS PHARMACEUTICALS, INC. STRONGLY ENCOURAGES YOU TO SEEK THE ADVICE OF YOUR OWN LEGAL AND FINANCIAL ADVISORS WITH RESPECT TO YOUR AWARD AND ITS TAX CONSEQUENCES. FORM OF NON-STATUTORY TIME-BASED STOCK OPTION AGREEME |
|
| February 27, 2024 |
Subsidiaries of the Registrant. EXHIBIT 21 SIGNIFICANT SUBSIDIARIES OF SUPERNUS PHARMACEUTICALS, INC. Name of Subsidiaries Jurisdiction of Organization MDD US Enterprises, LLC Delaware MDD US Operations, LLC Delaware Supernus Europe Ltd. United Kingdom Adamas Pharmaceuticals, LLC Delaware Adamas Operations, LLC Delaware Adamas Holdings, LLC Delaware Biscayne Neurotherapeutics, Inc. Delaware |
|
| February 27, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or |
|
| February 27, 2024 |
EXHIBIT 10.44 SUPERNUS PHARMACEUTICALS, INC. 2021 EQUITY INCENTIVE PLAN PERFORMANCE SHARE UNIT AWARD AGREEMENT This Performance Share Unit Award Agreement (the “Agreement”) is made and entered into as of , (the “Grant Date”). This Agreement evidences a performance share unit Award granted by Supernus Pharmaceuticals, Inc. (the “Company”) to the undersigned (“Participant”) pursuant to and subject t |
|
| February 27, 2024 |
EXHIBIT 10.42 SUPERNUS PHARMACEUTICALS, INC. 2021 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT SUPERNUS PHARMACEUTICALS, INC. STRONGLY ENCOURAGES YOU TO SEEK THE ADVICE OF YOUR OWN LEGAL AND FINANCIAL ADVISORS WITH RESPECT TO YOUR AWARD AND ITS TAX CONSEQUENCES. This Restricted Stock Unit Agreement (this “Agreement”) is made and entered into as of the date set forth below (the “Grant Date |
|
| February 27, 2024 |
EXHIBIT 97 Incentive Compensation Recoupment Policy of Supernus Pharmaceuticals, Inc. |
|
| February 27, 2024 |
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results Exhibit 99.1 Supernus Announces Fourth Quarter and Full Year 2023 Financial Results •Fourth quarter 2023 net sales of Qelbree® increased 97% to $46.4 million compared to fourth quarter 2022; Full year 2023 net sales of Qelbree increased 129% to $140.2 million compared to full year 2022. •Fourth quarter 2023 net sales of GOCOVRI® increased 10% to $32.0 million compared to fourth quarter 2022; Full |
|
| February 27, 2024 |
Form of Executive Retention Agreement. EXHIBIT 10.16 FORM OF EXECUTIVE RETENTION AGREEMENT THIS EXECUTIVE RETENTION AGREEMENT (this “Agreement”) is made and entered into this [·] day of [·], [·] (the “Effective Date”) by and between Supernus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [·] (the “Executive”). 1. Definitions. Capitalized terms used in this Agreement shall have the meanings set forth either in this S |
|
| February 27, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2023 or ☐ TRANSMISSION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-35518 SUPER |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2024 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or |
|
| February 14, 2024 |
EX-99.A 2 d740350dex99a.htm EX-99.A EXHIBIT A AGREEMENT TO FILE JOINT ACQUISITION STATEMENTS AGREEMENT made this [7th] day of FEBRUARY, 2024 by and between Delaware Funds by Macquarie,® Optimum Fund Trust and Macquarie ETF Trust listed on Annex A hereto, Macquarie Investment Management Business Trust, Macquarie Management Holdings, Inc, and the Macquarie Parties listed on Annex B hereto (collectiv |
|
| February 14, 2024 |
EX-99.B 3 d740350dex99b.htm EX-99.B EXHIBIT B Powers of Attorney for Macquarie Group Limited incorporated by reference to 13G filings made by Macquarie Group Limited on June 7, 2023. Page 13 of 13 |
|
| February 14, 2024 |
SUPN / Supernus Pharmaceuticals, Inc. / MACQUARIE GROUP LTD - SC 13G Passive Investment SC 13G 1 d740350dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 0)* Supernus Pharmaceuticals Inc (Name of Issuer) Common Shares (Title of Class of Securities) 868459108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| February 14, 2024 |
SUPN / Supernus Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2024 |
Exhibit 99.1 Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024 ROCKVILLE, Md., February 13, 2024 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Compa |
|
| February 13, 2024 |
SUPN / Supernus Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02020-supernuspharmaceutic.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Supernus Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 868459108 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate b |
|
| February 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or |
|
| February 5, 2024 |
Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent Exhibit 99.1 Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent ROCKVILLE, Md., February 5, 2024 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that the United States District Court for the District of New Jersey rule |
|
| February 5, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2024 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or o |
|
| January 19, 2024 |
SUPN / Supernus Pharmaceuticals, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us8684591089011924.txt us8684591089011924.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 4) SUPERNUS PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 868459108 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35518 SUPERNUS PHARMACEUTICALS, INC. |
|
| November 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or o |
|
| November 8, 2023 |
Supernus Announces Third Quarter 2023 Financial Results Exhibit 99.1 Supernus Announces Third Quarter 2023 Financial Results •Raises full year 2023 adjusted operating earnings (non-GAAP)(1) guidance range to $95 million to $110 million from previous range of $75 million to $100 million •Total revenues (GAAP) of $153.9 million in the third quarter of 2023; total revenues excluding Trokendi XR® net product sales (non-GAAP)(2), increased by 24% in the thi |
|
| November 2, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or o |
|
| November 2, 2023 |
Exhibit 99.1 Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA PDUFA Target Action Date of April 5, 2024 ROCKVILLE, Md., November 2, 2023 – Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and |
|
| October 25, 2023 |
Exhibit 99.1 Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023 ROCKVILLE, Md., October 25, 2023 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to rep |
|
| October 25, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2023 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or o |
|
| October 18, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2023 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or o |
|
| October 18, 2023 |
Exhibit 99.1 © 2023 Supernus Pharmaceuticals, Inc. All Rights Reserved. Supernus Pharmaceuticals R&D Day October 18, 2023 1 © 2023 Supernus Pharmaceuticals, Inc. All Rights Reserved. Introduction and Agenda 2 Jack Khattar President and Chief Executive Officer © 2023 Supernus Pharmaceuticals, Inc. All Rights Reserved. Safe Harbor Statement 3 This presentation and other matters discussed today or an |
|
| October 10, 2023 |
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device Exhibit 99.1 Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device ROCKVILLE, MD, October 9, 2023 – Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced it has resubmitted its New Drug Application (NDA) for its apomorphine infusion device (SP |
|
| October 10, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2023 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or or |
|
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2023 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or or |
|
| August 21, 2023 |
Bethany L. Sensenig Joins Supernus’ Board of Directors Exhibit 99.1 Bethany L. Sensenig Joins Supernus’ Board of Directors ROCKVILLE, MD, August 21, 2023 – Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Bethany L. Sensenig has joined the Supernus Board of Directors effective immediately. Ms. Se |
|
| August 10, 2023 |
Supernus Announces Second Quarter 2023 Financial Results Exhibit 99.1 Supernus Announces Second Quarter 2023 Financial Results •Qelbree® net product sales growth of 179% and 193% in the second quarter and first six months of 2023, respectively, compared to the same periods in 2022 –$31.0 million and $56.8 million of net product sales in the second quarter and first six months of 2023, respectively •GOCOVRI® net product sales growth of 17% and 16% in the |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or o |
|
| August 8, 2023 |
Supernus Announces Second Quarter 2023 Financial Results Exhibit 99.1 Supernus Announces Second Quarter 2023 Financial Results •Qelbree® net product sales growth of 179% and 193% in the first three months and first six months of 2023, respectively, compared to the same periods in 2022 –$31.0 million and $56.8 million of net product sales in the first three months and first six months of 2023, respectively •GOCOVRI® net product sales growth of 17% and 16 |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or org |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35518 SUPERNUS PHARMACEUTICALS, INC. |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or orga |
|
| July 24, 2023 |
Exhibit 99.1 Supernus Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 8, 2023 ROCKVILLE, Md., July 24, 2023 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or orga |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or orga |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35518 SUPERNUS PHARMACEUTICALS, INC. |
|
| May 9, 2023 |
Supernus Announces First Quarter 2023 Financial Results Exhibit 99.1 Supernus Announces First Quarter 2023 Financial Results •First quarter 2023 total revenues of $153.8 million, compared to $152.5 million in first quarter 2022 –Qelbree® net product sales of $25.8 million, compared to $8.3 million in first quarter 2022 –GOCOVRI® net product sales of $26.0 million, compared to $22.6 million in first quarter 2022 –Excluding net product sales of Trokendi |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or organi |
|
| May 1, 2023 |
DearSupernusStockholder, In2022,wecontinuedtoexecuteonourlong-termgrowthstrategyfocusingonsuccessfullytransitioning fromourlegacyandmatureproductstoourgrowthproducts. |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 FILED BY THE REGISTRANT x FILED BY A PARTY OTHER THAN THE REGISTRANT ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 FILED BY THE REGISTRANT ☒ FILED BY A PARTY OTHER THAN THE REGISTRANT ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 26, 2023 |
Exhibit 99.1 Supernus Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 9, 2023 ROCKVILLE, Md., April 25, 2023 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report fin |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2023 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or org |
|
| April 3, 2023 |
Supernus Announces Repayment of Convertible Notes Exhibit 99.1 Supernus Announces Repayment of Convertible Notes ROCKVILLE, Md., April 3, 2023 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that it has paid the total principal amount due of $402.5 million under its 0.625% Convertible Senior N |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or org |
|
| March 9, 2023 |
Subsidiaries of the Registrant. EXHIBIT 21 SIGNIFICANT SUBSIDIARIES OF SUPERNUS PHARMACEUTICALS, INC. Name of Subsidiaries Jurisdiction of Organization MDD US Enterprises, LLC Delaware MDD US Operations, LLC Delaware Supernus Europe Ltd. United Kingdom Adamas Pharmaceuticals, LLC Delaware Adamas Operations, LLC Delaware Adamas Holdings, LLC Delaware Biscayne Neurotherapeutics, Inc. Delaware |
|
| March 9, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2022 or ☐ TRANSMISSION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-35518 SUPER |
|
| March 9, 2023 |
EXECUTION COPY Exhibit 10.71 CERTAIN CONFIDENTIAL INFORMATION IDENTIFIED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SETTLEMENT AGREEMENT BY AND BETWEEN SUPERNUS PHARMACEUTICALS, INC. AND ZYDUS PHARMACEUTICAL (USA) INC. ZYDUS LIFESCIENCES LIMITED DATED AS OF DECEMBER 31, 2022 |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-35518 CUSIP Number: 868459 10 8 (Check one): Form 10-K Form 20-F Form 11-K Form 10-Q Form 10-D Form N-SAR Form N-CSR For Period Ended: December 31, 2022 Transition Report on Form 10-K Transition Report on Form 20-F Transition Report on Form 11-K Transition Report on |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or |
|
| February 28, 2023 |
Supernus Announces Fourth Quarter and Full Year 2022 Financial Results Exhibit 99.1 Supernus Announces Fourth Quarter and Full Year 2022 Financial Results •Full Year 2022 total revenues of $667.2 million, a 15% increase compared to full year 2021 •Fourth quarter 2022 Qelbree® net product sales of $23.6 million increased 29% compared to third quarter of 2022; Full year 2022 Qelbree net product sales of $61.3 million, compared to $9.9 million for full year 2021 •Execut |
|
| February 14, 2023 |
Supernus Enters Into $150 Million Credit Facility Exhibit 99.1 Supernus Enters Into $150 Million Credit Facility ROCKVILLE, MD, February 14, 2023 – Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced it entered into a credit line agreement (the “Credit Line”) with UBS Bank USA (“UBS”) providing the |
|
| February 14, 2023 |
SUPN / Supernus Pharmaceuticals Inc / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-supn123122a3.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* SUPERNUS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 868459108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statemen |
|
| February 14, 2023 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION IDENTIFIED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. ab UBS Bank USA Credit Line Agreement Variable Credit Line Account Number: (if applicable) [*] [*] Fixed Credit Line Account Number: (if applicable) [*] [*] Internal Use Only B |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or o |
|
| February 10, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2023 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or o |
|
| February 10, 2023 |
Exhibit 99.1 Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 28, 2023 ROCKVILLE, Md., February 9, 2023 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Compan |
|
| February 9, 2023 |
SUPN / Supernus Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01991-supernuspharmaceutic.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Supernus Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 868459108 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate |
|
| January 23, 2023 |
SUPN / Supernus Pharmaceuticals Inc / BlackRock Inc. Passive Investment SC 13G/A 1 us8684591089012323.txt us8684591089012323.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) SUPERNUS PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 868459108 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35518 SUPERNUS PHARMACEUTICALS, INC. |
|
| November 8, 2022 |
Supernus Announces Third Quarter 2022 Financial Results Exhibit 99.1 Supernus Announces Third Quarter 2022 Financial Results ?Third quarter 2022 total revenues of $177.4 million, a 19% increase compared to third quarter 2021 ?Increasing full year 2022 operating earnings guidance to $35 million to $45 million, from $20 million to $40 million previously ?Increasing full year 2022 total revenues guidance to $650 million to $680 million, from $640 million |
|
| November 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or o |
|
| October 25, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2022 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or o |
|
| October 25, 2022 |
Exhibit 99.1 Supernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 8, 2022 ROCKVILLE, Md., October 25, 2022 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to rep |
|
| October 11, 2022 |
Supernus Provides Regulatory Update on SPN-830 Exhibit 99.1 Supernus Provides Regulatory Update on SPN-830 ROCKVILLE, Md., October 10, 2022 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the SPN-8 |
|
| October 11, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2022 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or o |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35518 SUPERNUS PHARMACEUTICALS, INC. |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or org |
|
| August 4, 2022 |
Supernus Announces Second Quarter 2022 Financial Results Exhibit 99.1 Supernus Announces Second Quarter 2022 Financial Results ?Second quarter 2022 total revenues of $170.1 million, a 20% increase compared to second quarter 2021 ?Second quarter 2022 GAAP operating earnings of $11.3 million; second quarter 2022 non-GAAP operating earnings of $37.6 million ?Qelbree? continued its growth trajectory, with 62,938 prescriptions in second quarter 2022, a 33% i |
|
| July 26, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2022 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or orga |
|
| July 26, 2022 |
EX-99.1 2 ex99107-25x2022.htm EX-99.1 Exhibit 99.1 Supernus Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022 ROCKVILLE, Md., July 25, 2022 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announc |
|
| June 17, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2022 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or orga |
|
| June 9, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or organ |
|
| June 9, 2022 |
Exhibit 99.1 ? 2022 Supernus Pharmaceuticals, Inc. All Rights Reserved. 1 Supernus Pharmaceuticals Jefferies Healthcare Conference June 2022 ? 2022 Supernus Pharmaceuticals, Inc. All Rights Reserved. Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward - looking statements within the meaning of the federal securit |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35518 SUPERNUS PHARMACEUTICALS, INC. |
|
| May 10, 2022 |
SEC FILE NUMBER: 001-35518 CUSIP NUMBER: 868459 10 8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or organi |
|
| May 9, 2022 |
Supernus Announces First Quarter 2022 Financial Results Exhibit 99.1 Supernus Announces First Quarter 2022 Financial Results ?First quarter 2022 total revenues of $152.5 million, a 16% increase compared to first quarter 2021 ?First quarter 2022 net earnings and diluted earnings per share (GAAP) were $25.6 million and $0.43, respectively ?First quarter 2022 GAAP operating income of $2.0 million; first quarter 2022 non-GAAP operating income of $28.0 mill |
|
| May 4, 2022 |
Exhibit 99.1 Supernus Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 9, 2022 ROCKVILLE, Md., May 2, 2022 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financ |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2022 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or organi |
|
| May 3, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2022 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or organi |
|
| May 3, 2022 |
Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults Exhibit 99.1 Supernus Announces FDA Approval of Qelbree? for the Treatment of ADHD in Adults ?First novel, nonstimulant option for adults with ADHD in 20 years ?ADHD affects an estimated 10 million adults in the U.S. ROCKVILLE, Md., April 29, 2022 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen |
|
| May 2, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 FILED BY THE REGISTRANT ? FILED BY A PARTY OTHER THAN THE REGISTRANT ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? Definitive Proxy |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 FILED BY THE REGISTRANT x FILED BY A PARTY OTHER THAN THE REGISTRANT ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 13, 2022 |
Supernus Reports Final Audited Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 Supernus Reports Final Audited Fourth Quarter and Full Year 2021 Financial Results ?Annual Report on Form 10-K filed on April 13, 2022 ?Reiterates full year 2022 financial guidance provided on February 28, 2022 and reiterated on April 4, 2022 ROCKVILLE, Md., April 13, 2022 ? Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercial |
|
| April 13, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2022 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or org |
|
| April 13, 2022 |
Subsidiaries of the Registrant. EXHIBIT 21 SUBSIDIARIES OF SUPERNUS PHARMACEUTICALS, INC. Name of Subsidiaries Jurisdiction of Organization MDD US Enterprises, LLC Delaware MDD US Operations, LLC Delaware Supernus Europe Ltd. United Kingdom Adamas Pharmaceuticals, Inc. Delaware Adamas Operations, LLC Delaware Adamas Holdings, LLC Delaware Biscayne Neurotherapeutics, Inc. Delaware |
|
| April 13, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2021 or ? TRANSMISSION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-35518 SUPER |
|
| April 5, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2022 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or orga |
|
| April 5, 2022 |
Supernus Provides Update on Filing of Annual Report and Reiterates Full Year 2022 Financial Guidance EX-99.1 2 ex99104-04x2022.htm EX-99.1 Exhibit 99.1 Supernus Provides Update on Filing of Annual Report and Reiterates Full Year 2022 Financial Guidance ROCKVILLE, Md., April 4, 2022 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it expect |
